1. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
- Author
-
Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, and Xiang Gao
- Subjects
Crohn’s disease ,ustekinumab ,vedolizumab ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Ustekinumab and vedolizumab are both effective for treating Crohn’s disease (CD). However, no head-to-head trials have been conducted thus far. We aimed to compare the effectiveness of ustekinumab and vedolizumab in CD patients either naïve or exposed to tumor necrosis factor-alpha inhibitors (TNFi). Methods: Patients treated with vedolizumab or ustekinumab for luminal CD were included from six centers in China from May 2020 to July 2023. Steroid-free remission, clinical remission, objective response, and remission at Weeks 26 and 52 were evaluated in a retrospective multicenter propensity score–weighted cohort. Findings: A total of 536 patients were included (386 ustekinumab, and 150 vedolizumab). After adjustment, ustekinumab showed higher rates of clinical remission (56.4% vs. 47.8%, P = 0.005), steroid-free remission (55.4% vs. 46.1%, P = 0.003), and objective response (67.8% vs. 42.7%, P
- Published
- 2023
- Full Text
- View/download PDF